Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Employment agrmnt
Quarterly results
Acq. announced
Consulting agrmnt
Director departure
Appointed director
|
|
PANACEA LIFE SCIENCES HOLDINGS, INC. (EXDI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Entered into consulting agreement|
Docs:
|
"FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES N-7 CONVERTIBLE PREFERRED STOCK The undersigned, Chief Executive Officer of Panacea Life Sciences Holdings, Inc., a Nevada corporation , DOES HEREBY CERTIFY that the following resolutions were duly adopted by the Board of Directors of the Corporation by unanimous written consent on June 30, 2023; WHEREAS, the Board of Directors is authorized within the limitations and restrictions stated in the Articles of Incorporation of the Corporation, as amended, to provide by resolution or resolutions for the issuance of 50,000,000 shares of Preferred Stock, par value $0.0001 per share, of the Corporation, in such series and with such designations, preferences and relative, participating, optional or other special rig...",
"FORM OF ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT is entered into as of June 30, 2023 , by and among Panacea Life Sciences Holdings, Inc., a Nevada corporation, or its assigns , Lizard Juice, LLC, a Delaware limited liability company , Gary Wilder, an individual resident of Florida , New Age Distribution, LLC, a Florida limited liability company , and N7 Enterprises, Inc., a Florida corporation and the parent company of Lizard Juice and New Age Distribution , and collectively together with Lizard Juice, Wilder and New Age Distribution, its and their respective subsidiaries, affiliates and assigns, the “ Seller ” or “ Sellers ”), and each of the Holders . Sellers and PLSH, as applicable, and Holders, as applicable, are sometimes referred to individually as a “ Party ” and colle...",
"FORM OF BILL OF SALE THIS BILL OF SALE is entered into on September 30, 2023, y and among Panacea Life Sciences Holdings, Inc., a Nevada corporation, or its assigns , Lizard Juice, LLC, a Delaware limited liability company , Gary Wilder, an individual resident of Florida , New Age Distribution, LLC, a Florida limited liability company , and N7 Enterprises, Inc., a Florida corporation and the parent company of Lizard Juice and New Age Distribution , for the benefit of Buyer. Recitals A. Sellers and Buyer, among others, entered into that certain Asset Purchase Agreement dated June 30, 2023 , whereby Buyer agreed to purchase the Assets from Sellers; and B. Capitalized terms not defined herein have the respective meanings ascribed to them in the APA. NOW THEREFORE, Sellers certifies as follows...",
"FORM OF PLEDGE AND SECURITY AGREEMENT This PLEDGE AND SECURITY AGREEMENT , made as of June 30, 2023, by and among Gary Wilder, a Florida resident and Panacea Life Sciences Holdings, Inc., a Nevada corporation . RECITALS WHEREAS, the Parties entered into that certain asset purchase agreement dated June 30, 2023 , pursuant to which, among other things, Pledgor will acquire 31,000 shares of Series N7 Convertible Preferred Stock of Panacea Life Sciences Holdings, Inc. , convertible into 3,100,000 common shares of the Company’ s common stock, par value $0.0001 ; and WHEREAS, Pledgor has agreed to pledge the Pledged Shares for the period beginning at the Signing Date of the Asset Purchase Agreement and ending twenty-four months thereafter to secure the indemnification obligations of the Sellers ...",
"CONSULTING AGREEMENT",
"Panacea Life Sciences Holdings, Inc. 16194 West 45th Drive Golden, CO 80403 September 30, 2023 VIA EMAIL Gary Wilder 8565 Somerset Dr., Suite A Largo, FL 33770",
"FORM OF LEAK OUT AGREEMENT This LEAK-OUT AGREEMENT is made as of September 30, 2023 by and between Panacea Life Sciences Holdings, Inc. a Nevada corporation, , and the undersigned of the Company. WHEREAS, to ensure the development of an orderly trading market in the Company’ s common stock , the Company and the Stockholder intend to enter into this Agreement to provide for the circumstances under which the Stockholder may sell or otherwise dispose of shares of the Company’ s securities; and WHEREAS, pursuant to that certain Asset Purchase Agreement dated as of June 30, 2023 , Stockholder is the holder of shares of Series N7 Preferred Stock of the Company . NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement and the Asset Purchase Agreement, and for other go..." |
|
| 10/02/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT is entered into as of July 3, 2023 , by and among Panacea Life Sciences Holdings, Inc., a Nevada corporation, or its assigns , Lizard Juice, LLC, a Delaware limited liability company , Gary Wilder, an individual resident of Florida , New Age Distribution, LLC, a Florida limited liability company , and N7 Enterprises, Inc., a Florida corporation and the parent company of Lizard Juice and New Age Distribution , and collectively together with Lizard Juice, Wilder and New Age Distribution, its and their respective subsidiaries, affiliates and assigns, the “ Seller ” or “ Sellers ”), and each of the Holders . Sellers and PLSH, as applicable, and Holders, as applicable, are sometimes referred to individually as a “ Party ” and collectively a..." |
|
| 02/14/2023 |
8-K
| Quarterly results |
| 01/23/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/22/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Quarterly results |
| 03/04/2022 |
8-K
| Quarterly results |
| 12/29/2021 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 12/20/2021 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 12/17/2021 |
8-K/A
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Audited financial statements of Panacea Life Sciences, Inc. for the years ended December 31, 2020 and 2019 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Panacea Life Sciences, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of Panacea Life Sciences, Inc. as of December 31, 2020 and 2019, and the related statements of operations, stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2020, and the related notes . In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the two-...",
"Unaudited pro forma condensed combined financial information On June 30, 2021, Panacea Life Sciences Holdings, Inc. acquired Panacea Life Sciences, Inc. pursuant to a Securities Exchange Agreement with the shareholders of Panacea including its founder Leslie Buttorff and 22nd Century Group, Inc., , a principal investor. All share amounts have been retroactively adjusted to give effect to the 1-for-28 reverse stock split of EXDI’ s common stock which was effected on October 25, 2021 ." |
|
| 12/01/2021 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 11/24/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"RECITALS",
"SENIOR CONVERTIBLE NOTE OF PANACEA LIFE SCIENCES HOLDINGS, INC. Issuance Date: November 18, 2021 Original Principal Amount: $_________ FOR VALUE RECEIVED, Panacea Life Sciences Holdings, Inc., a Nevada corporation , hereby promises to pay to the order of ________________ or its registered assigns the amount set forth above as the Original Principal Amount when due, whether upon the Maturity Date, or upon acceleration, redemption or otherwise and, if either an SEC Exchange Act Compliance Failure or an Event of Default has occurred and is continuing, to pay interest on any outstanding Principal, in the case of an SEC Exchange Act Compliance Failure, at the Interest Rate , and in the case of an Event of Default, at the Default Rate , in each case until the same becomes due and payable, whethe...",
"WARRANT TO PURCHASE COMMON STOCK OF PANACEA LIFE SCIENCES HOLDINGS, INC. Warrant Shares: 785,715 Original Issuance Date: November 18, 2021 Initial Exercise Date: May 18, 2022 Panacea Life Sciences Holdings, Inc., a Nevada corporation hereby grants to ______________ or its assigns , the right to purchase up to 785,715 shares of the Company’ s common stock, par value $0.0001 per share , upon the terms and subject to the conditions of this Warrant to Purchase Common Stock . This Warrant may be exercised in accordance with its terms at any time on or after the Initial Exercise Date and on or prior to 5:00 p.m. on May 18, 2027 . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2 of this Warrant. Section 1 . Definition...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of November 18, 2021, between Panacea Life Sciences Holdings, Inc., a Nevada corporation , and ________________, an _______________ . This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and the Investor . The Company and the Investor hereby agrees as follows: 1. Definitions . Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “Advice” shall have the meaning set forth in Section 6. “Effectiveness Date” means, with respect to the Initial Re..." |
|
| 10/29/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C-2 CONVERTIBLE PREFERRED STOCK The undersigned, Chief Executive Officer of Exactus, Inc., a Nevada corporation , DOES HEREBY CERTIFY that the following resolutions were duly adopted by the Board of Directors of the Corporation by unanimous written consent on October 21, 2021; WHEREAS, the Board of Directors is authorized within the limitations and restrictions stated in the Articles of Incorporation of the Corporation, as amended, to provide by resolution or resolutions for the issuance of 50,000,000 shares of Preferred Stock, par value $0.0001 per share, of the Corporation, in such series and with such designations, preferences and relative, participating, optional or other special rights and qualifications, limi..." |
|
| 10/21/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/16/2021 |
8-K
| Quarterly results |
| 07/08/2021 |
8-K
| Quarterly results |
| 07/07/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"Amended Articles of Incorporation",
"Amended Bylaws",
"Form of Securities Exchange Agreement",
"Form of Indemnification Agreement",
"Exactus Joins with Panacea Life Sciences to Create Premier CBD Wellness Platform Leslie Buttorff, Founder of Panacea, To Lead Combined Companies as Chief Executive Officer DELRAY BEACH, FL / July 1, 2021 / Exactus, Inc. a leading supplier of hemp-derived ingredients , today announced the acquisition of Panacea Life Sciences, Inc. Panacea, which was founded by Leslie Buttorff, in 2017 as a woman-owned business, which attracted $20 million in initial investments which were followed up with a $14 million in investment from 22nd Century Group, Inc. during 2019, a leading plant biotechnology company focused on technology to decrease nicotine in tobacco plants also uses its expertise for genetic engineering of hemp and cannabis plants to modify cannabinoid levels used in manufacturing CBD, CBG ..." |
|
| 06/28/2021 |
8-K
| Quarterly results |
| 04/30/2021 |
8-K
| Quarterly results |
| 04/06/2021 |
8-K
| Quarterly results |
| 02/17/2021 |
8-K
| Quarterly results |
| 12/28/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/03/2020 |
8-K
| Unregistered Sales of Equity Securities |
| 09/21/2020 |
8-K
| Quarterly results |
| 07/01/2020 |
8-K
| Quarterly results |
| 06/30/2020 |
8-K
| Quarterly results |
| 06/30/2020 |
8-K
| Quarterly results |
| 06/22/2020 |
8-K
| Quarterly results |
| 06/16/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/26/2020 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/15/2020 |
8-K
| Quarterly results |
|
|
|